Check Cap Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.66 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Check Cap Ltd had its IPO on 2015-02-19 under the ticker symbol CHEK.
The company operates in the Healthcare sector and Diagnostics & Research industry. Check Cap Ltd has a staff strength of 81 employees.
Shares of Check Cap Ltd opened at $1.33 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $1.22 - $1.35, and closed at $1.32.
This is a +0.76% increase from the previous day's closing price.
A total volume of 90,189 shares were traded at the close of the day’s session.
In the last one week, shares of Check Cap Ltd have slipped by -56%.
Check Cap Ltd's Key Ratios
Check Cap Ltd has a market cap of $7.66 million, indicating a price to book ratio of 0.3628 and a price to sales ratio of 0.
In the last 12-months Check Cap Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-21077000. The EBITDA ratio measures Check Cap Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Check Cap Ltd’s operating margin was 0% while its return on assets stood at -24.29% with a return of equity of -41.39%.
In Q3, Check Cap Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Check Cap Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Check Cap Ltd’s profitability.
Check Cap Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3492. Its price to sales ratio in the trailing 12-months stood at 0.
Check Cap Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $49.55 million
- Total Liabilities
- $3.83 million
- Operating Cash Flow
- $1.93 million
- Capital Expenditure
- Dividend Payout Ratio
Check Cap Ltd ended 2023 with $49.55 million in total assets and $0 in total liabilities. Its intangible assets were valued at $49.55 million while shareholder equity stood at $44.93 million.
Check Cap Ltd ended 2023 with $0 in deferred long-term liabilities, $3.83 million in other current liabilities, 83653000.00 in common stock, $-123580000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.35 million and cash and short-term investments were $45.60 million. The company’s total short-term debt was $353,000 while long-term debt stood at $0.
Check Cap Ltd’s total current assets stands at $46.54 million while long-term investments were $0 and short-term investments were $36.25 million. Its net receivables were $0 compared to accounts payable of $849000.00 and inventory worth $0.
In 2023, Check Cap Ltd's operating cash flow was $1.93 million while its capital expenditure stood at $72000.
Comparatively, Check Cap Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Check Cap Ltd stock is currently trading at $1.32 per share. It touched a 52-week high of $9.198 and a 52-week low of $9.198. Analysts tracking the stock have a 12-month average target price of $15.
Its 50-day moving average was $3.2 and 200-day moving average was $4.86 The short ratio stood at 0.35 indicating a short percent outstanding of 0%.
Around 320.6% of the company’s stock are held by insiders while 168.2% are held by institutions.
Frequently Asked Questions About Check Cap Ltd
Similar Industry Stocks (Diagnostics & Research)
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.